Anti-depressants, suicide, and drug regulation
Anti-depressants, suicide, and drug regulation
复制标题
DOI：
10.1002/pam.20089
复制
发表时间：
2005-03-01
影响因子：
3.8
通讯作者：
Marcotte, DE
中科院分区：
文献类型：
--
作者：
Ludwig, J;Marcotte, DE
政策制定者越来越担心，一类相对较新的抗抑郁药物——选择性血清素再摄取抑制剂（SSRI）可能会增加至少部分患者（尤其是儿童）的自杀风险。由于样本量小和其他限制，之前的随机试验没有提供关于这个问题的信息。利用各国 SSRI 销售和自杀率随时间变化的变化，我们发现，人均服用一颗药丸的数量增加（比 1999 年的水平增加 13%）与自杀率降低 2.5% 相关，这种关系对于成人而言比儿童更为明显。我们的研究结果表明，尽管政策制定者对儿科使用 SSRI 保持谨慎态度是正确的，但扩大成人使用 SSRI 的机会可能是拯救生命的一种经济有效的方法。 (c) 2005 年公共政策分析与管理协会。
Policymakers are increasingly concerned that a relatively new class of anti-depressant drugs, selective serotonin re-uptake inhibitors (SSRI), may increase the risk of suicide for at least some patients, particularly children. Prior randomized trials are not informative on this question because of small sample sizes and other limitations. Using variation across countries over time in SSRI sales and suicide, we find that an increase of one pill per capita (a 13 percent increase over 1999 levels) is associated with a 2.5 percent reduction in suicide rates, a relationship that is more pronounced for adults than for children. Our findings suggest that expanding access to SSRIs for adults may be a cost-effective way to save lives, although policymakers are right to remain cautious about pediatric use of SSRIs. (c) 2005 by the Association for Public Policy Analysis and Management.